Thymosin Alpha 1
Lung Cancer Metastatic
The First Affiliated Hospital of Xiamen UniversityPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Lung Cancer Metastatic cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rhgm-Csf Peking University Cancer Hospital & Institute | Phase 2 | B |
Evolocumab Eziafa Oduah, MD, PhD, MPH | Phase 2 | CCC |
Dabrafenib Sun Yat-sen University | Phase 2 | CCC |
Recombinant Human Gm-Csf The First Affiliated Hospital of Xiamen University | Phase 2 | CCC |
Capmatinib SWOG Cancer Research Network | Phase 2 | CCC |
View all 9 →
Same molecule, other indications
Thymosin Alpha 1 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →